Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MicroRNA-200c Promotes Epithelial-Mesenchymal Transition of Lens Epithelial Cells by Activating the Yes-Associated Protein Signaling Pathway.

Journal of ophthalmology·2026
Same author

Facilely Constructing Li<sub>3</sub>P/Fe Dual-Conductive Interface for High-Performance Garnet-Based Solid-State Lithium Metal Batteries.

ACS applied materials & interfaces·2026
Same author

Editorial: Unravelling the wildlife gut microbiome: the crucial role of gut microbiomes in wildlife conservation strategies.

Frontiers in microbiology·2026
Same author

Effect of crop rotation and crop succession on microorganisms and yield of tobacco rhizosphere soil.

BMC microbiology·2026
Same author

The Dichloromethane Fraction of <i>Sanguisorba tenuifolia</i> Inhibits Inflammation in Cells Through Modulation of the p38/ERK/MAPK and NF-κB Signaling Pathway.

International journal of molecular sciences·2025
Same author

Cyperus esculentus protein/tea polyphenol composite nanoparticles for enhanced stability of anthocyanins in Pickering emulsions.

Journal of the science of food and agriculture·2025

Related Experiment Video

Updated: Aug 29, 2025

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K

Multitargeting Strategy Using Tetrathiomolybdate and Lenvatinib: Maximizing Antiangiogenesis Activity in a

Li Nan1, Wan Yuan2, Chen Guodong1

  • 1Department of Interventional Radiology, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou 510180, China.

Anti-Cancer Agents in Medicinal Chemistry
|September 9, 2022
PubMed
Summary

Copper chelator ammonium tetrathiomolybdate (TM) combined with lenvatinib significantly suppresses hepatocellular carcinoma growth by reducing tumor angiogenesis. This combination therapy shows promise for clinical application in treating liver cancer.

Keywords:
Liver tumorangiogenesiscombination therapycoppercopper chelatorlenvatinib

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Related Experiment Videos

Last Updated: Aug 29, 2025

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Copper plays a role in tumor progression.
  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • Anti-angiogenesis therapies are crucial in cancer treatment.

Purpose of the Study:

  • To investigate the anti-tumor effects of ammonium tetrathiomolybdate (TM), a copper chelator, in combination with lenvatinib.
  • To evaluate the multi-anti-angiogenesis activity of this combination therapy in hepatocellular carcinoma.
  • To determine the impact on tumor growth, vascular endothelial growth factor (VEGF), and microvessel density (MVD).

Main Methods:

  • Hepa1-6 hepatoma cells were implanted in C57 mice.
  • Mice were randomized into five groups: TM, Lenvatinib, TM+Lenvatinib, Control, and Copper (II) Gluconate.
  • Tumor weight, volume, serum/intratumoral copper levels, VEGF expression, and MVD were analyzed post-treatment.

Main Results:

  • Copper concentrations correlated positively with tumor load.
  • The combination of TM and lenvatinib significantly reduced tumor weight and volume compared to controls.
  • Combined therapy led to decreased VEGF expression and MVD, indicating reduced angiogenesis.

Conclusions:

  • Copper promotes tumor progression; copper chelation suppresses tumor growth.
  • The combination of TM and lenvatinib exhibits potent anti-angiogenesis activity against HCC.
  • This combination therapy offers a promising strategy for hepatocellular carcinoma treatment.